SLDB Stock Summary and Trading Ideas (Solid Biosciences | NASDAQ:SLDB)

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Solid Biosciences trades on the NASDAQ stock market under the symbol SLDB.

As of February 20, 2026, SLDB stock price declined to $5.71 with 647,004 million shares trading.

SLDB has a beta of 2.05, meaning it tends to be more sensitive to market movements. SLDB has a correlation of 0.09 to the broad based SPY ETF.

SLDB has a market cap of $444.63 million. This is considered a Small Cap stock.

In the last 3 years, SLDB traded as high as $15.05 and as low as $1.81.

The top ETF exchange traded funds that SLDB belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

SLDB has underperformed the market in the last year with a price return of -4.8% while the SPY ETF gained +14.1%. However, in the short term, SLDB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +28.0% vs +6.0% return in SPY. But in the last 2 weeks, SLDB shares have been beat by the market, returning -12.4% compared to an SPY return of -0.2%.

SLDB support price is $5.55 and resistance is $6.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLDB shares will trade within this expected range on the day.